Abstract
No optimal treatment modality is currently available for the treatment of recurrent epistaxis in HHT. In this review, different therapeutic concepts are discussed together with their pathophysiologic background. Patients often profess a preventive effect for nasal ointments and use packings which can be self-administed in the case of bleeding. An effective first-line treatment for physicians is the endonasal laser coagulation or argon plasma coagulation. A second line surgical procedure is septodermoplasty according to Saunders which can provide long-lasting relief if performed correctly. There have been reports on antifibrinolytic agents and hormones, but their efficacy has yet to be determined.
Keywords: Rendu-Osler-Weber disease, hereditary haemorrhagic telangiectasia, laser therapy, septodermoplasty, review
Current Pharmaceutical Design
Title: Treatment of Recurrent Epistaxis in HHT
Volume: 12 Issue: 10
Author(s): U. W. Geisthoff, M. L. Fiorella and R. Fiorella
Affiliation:
Keywords: Rendu-Osler-Weber disease, hereditary haemorrhagic telangiectasia, laser therapy, septodermoplasty, review
Abstract: No optimal treatment modality is currently available for the treatment of recurrent epistaxis in HHT. In this review, different therapeutic concepts are discussed together with their pathophysiologic background. Patients often profess a preventive effect for nasal ointments and use packings which can be self-administed in the case of bleeding. An effective first-line treatment for physicians is the endonasal laser coagulation or argon plasma coagulation. A second line surgical procedure is septodermoplasty according to Saunders which can provide long-lasting relief if performed correctly. There have been reports on antifibrinolytic agents and hormones, but their efficacy has yet to be determined.
Export Options
About this article
Cite this article as:
Geisthoff W. U., Fiorella L. M. and Fiorella R., Treatment of Recurrent Epistaxis in HHT, Current Pharmaceutical Design 2006; 12 (10) . https://dx.doi.org/10.2174/138161206776361255
DOI https://dx.doi.org/10.2174/138161206776361255 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design Treatment of Choroidal Neovascularization in High Myopia
Current Drug Targets Molecular Modeling of Sulfonylmorpholinopyrimidines as the Ataxia Telangiectasis Mutated and RAD3-related (ATR) Protein Kinase Inhibitors by Computational Explorations
Letters in Drug Design & Discovery Medical Treatment of Chronic Venous Insufficiency
Vascular Disease Prevention (Discontinued) Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency
Current Vascular Pharmacology Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension
Current Vascular Pharmacology Editorial [Hot Topic: Targeting Mast Cells and Basophils in Allergy and Beyond: Emerging Concepts (Executive Guest Editor: Petr Heneberg)]
Current Pharmaceutical Design Arthropathy in Patients with CREST Variant Scleroderma
Current Rheumatology Reviews